$228.00
You’ll be briefly redirected to Link Money, our secure ACH payment partner, to connect your bank and complete payment.– Your bank login is never visible to or stored by us – Encrypted, bank-level security – A standard, trusted payment process
The FOXO4 peptide is a laboratory-engineered D-retro inverso (DRI) peptide designed to interfere with the FOXO4–p53 interaction. It is used in research focused on cellular senescence, stress-response signaling, and mechanisms involved in targeted apoptosis within dysfunctional cells.
FOXO4 studies commonly examine senescent cells, including senescent fibroblasts, chondrocytes, Leydig cells, and certain senescent cancer cell models. These cells have exited the cell cycle but remain metabolically active and are associated with inflammation and altered tissue function in aging biology. Research explores how FOXO4 signaling contributes to the senescence-associated secretory phenotype and tissue homeostasis changes.
Apoptosis is a central focus of FOXO4 peptide research. In experimental systems, researchers evaluate how disrupting the FOXO4–p53 interaction may influence apoptosis in senescent or dysfunctional cells while preserving healthy cells. The term “senescent cell clearance” refers to laboratory investigation of these molecular processes, not therapeutic outcomes.
No. The FOXO4 DRI peptide is not approved as a treatment, supplement, or injectable product. References to FOXO4 DRI therapy appear only in academic research contexts. Aion Aminos supplies the peptide exclusively for laboratory research as a lyophilized powder, with handling, storage, and use governed by institutional protocols rather than dosing or administration guidance.
